CR20150097A - Composición inmunogénica - Google Patents

Composición inmunogénica

Info

Publication number
CR20150097A
CR20150097A CR20150097A CR20150097A CR20150097A CR 20150097 A CR20150097 A CR 20150097A CR 20150097 A CR20150097 A CR 20150097A CR 20150097 A CR20150097 A CR 20150097A CR 20150097 A CR20150097 A CR 20150097A
Authority
CR
Costa Rica
Prior art keywords
immunogenic composition
acetylated
aureus
present application
application relates
Prior art date
Application number
CR20150097A
Other languages
English (en)
Inventor
Philippe Denoel
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606416A external-priority patent/GB0606416D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CR20150097A publication Critical patent/CR20150097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere a composiciones inmunogénicas que comprenden el polisacárido u oligosacárido capsular tipo 5 y/u 8 de S. aureus, que está entre 30-100% O-acetilado.
CR20150097A 2006-03-30 2015-02-25 Composición inmunogénica CR20150097A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78724906P 2006-03-30 2006-03-30
US78758706P 2006-03-30 2006-03-30
GB0606416A GB0606416D0 (en) 2006-03-30 2006-03-30 Immunogenic composition
PCT/EP2007/053057 WO2007113222A2 (en) 2006-03-30 2007-03-29 Immunogenic composition

Publications (1)

Publication Number Publication Date
CR20150097A true CR20150097A (es) 2015-04-14

Family

ID=38515803

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10348A CR10348A (es) 2006-03-30 2008-10-07 Composicion inmunogenica
CR20150097A CR20150097A (es) 2006-03-30 2015-02-25 Composición inmunogénica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR10348A CR10348A (es) 2006-03-30 2008-10-07 Composicion inmunogenica

Country Status (19)

Country Link
US (2) US20100021503A1 (es)
EP (4) EP2476433A1 (es)
JP (1) JP2009531387A (es)
KR (1) KR101541383B1 (es)
CN (1) CN103169960A (es)
AU (2) AU2007233705B2 (es)
BR (1) BRPI0710210A2 (es)
CA (1) CA2647441C (es)
CR (2) CR10348A (es)
EA (2) EA020459B1 (es)
IL (2) IL193565A (es)
MA (1) MA30343B1 (es)
MX (1) MX337528B (es)
MY (1) MY148405A (es)
NO (1) NO20083722L (es)
NZ (2) NZ595178A (es)
SG (1) SG170090A1 (es)
WO (1) WO2007113222A2 (es)
ZA (1) ZA200808246B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295520B8 (en) 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
US8146781B2 (en) * 2007-08-09 2012-04-03 Huhtamaki, Inc. Dispenser for viscous condiments
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
AU2009222105B2 (en) 2008-03-03 2012-05-17 Novartis Ag Compounds and compositions as TLR activity modulators
BRPI0910884A2 (pt) * 2008-04-16 2015-10-06 Glaxonsmithkline Biolog S A composição imunogênica, método para tratar ou prevenir infecção ou doença estafilocócicas, e, uso de uma composição imunogênica.
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
KR20170102039A (ko) 2009-04-03 2017-09-06 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
US8568735B2 (en) * 2009-06-22 2013-10-29 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
MY158231A (en) * 2009-06-22 2016-09-15 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
AU2010310919B2 (en) 2009-10-30 2015-05-07 Glaxosmithkline Biologicals S.A. Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
KR101853513B1 (ko) 2010-03-23 2018-04-30 노파르티스 아게 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 ｔｌｒ2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
JP6339366B2 (ja) 2010-05-06 2018-06-06 グリコヴァキシン アーゲー 莢膜グラム陽性菌のバイオコンジュゲートワクチン
KR20130093084A (ko) 2010-07-02 2013-08-21 더 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
JP5557328B2 (ja) * 2010-10-07 2014-07-23 Ｎｏｋ株式会社 中空糸炭素膜の製造方法
US20130259896A1 (en) * 2010-12-22 2013-10-03 Lakshmi Khandke Stable Immunogenic Compositions of Staphylococcus Aureus Antigens
WO2012170097A2 (en) * 2011-03-16 2012-12-13 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
USRE48137E1 (en) 2012-03-05 2020-08-04 University Of Maryland, Baltimore Multivalent vaccine protection from Staphylococcus aureus infection
EP2636750A1 (en) 2012-03-06 2013-09-11 Roche Diagniostics GmbH Compatible solute ectoine as well as derivatives thereof for enzyme stabilization
EP3805395A1 (en) 2012-04-26 2021-04-14 University Of Chicago Staphylococcal coagulase antigens and methods of their use
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
US20170000875A1 (en) 2013-12-02 2017-01-05 Arytha Biosciences, Llc Toxoid preparation and uses thereof
CN106163504B (zh) 2014-03-20 2021-02-09 加利福尼亚大学董事会 水凝胶毒素-吸收或结合纳米颗粒
BE1023004A1 (fr) 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
CN107530285B (zh) 2015-04-29 2021-07-27 加利福尼亚大学董事会 使用纳米粒子解毒
GB201600075D0 (en) * 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
US11214600B2 (en) * 2016-02-12 2022-01-04 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
JP7296386B2 (ja) * 2017-09-05 2023-06-22 スカラブ ゲノミクス， エルエルシー 組換えタンパク質の発現を改善するための方法および組成物
JP7362667B2 (ja) 2018-02-12 2023-10-17 イニミューン・コーポレーション Ｔｏｌｌ様受容体リガンド
WO2021041721A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5425946A (en) * 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
ES2243926T3 (es) 1993-02-05 2005-12-01 Smithkline Beecham Plc Proteina de union de fibronectina; anticuerpo monoclonal y su uso para prevenir la adhesion bacteriana.
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
GB9521146D0 (en) 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
ATE309271T1 (de) 1996-05-16 2005-11-15 Texas A & M Univ Sys Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
WO1997048440A1 (en) 1996-06-18 1997-12-24 Alza Corporation Device for enhancing transdermal agent delivery or sampling
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2195190T3 (es) 1996-12-20 2003-12-01 Alza Corp Dispositivo y metodo para mejorar el flujo de agente transdermico.
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
CA2310217A1 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
HUP0102475A3 (en) 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
DE69940157D1 (en) 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
DK1096952T3 (da) * 1998-07-15 2008-08-25 Brigham & Womens Hospital Polysaccharidvaccine mod stafylokok-infektioner
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
EP2311944A1 (en) 1998-08-31 2011-04-20 The Provost, Fellows and Scholars of the College Of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
CA2340304C (en) * 1998-08-31 2012-12-04 Inhibitex, Inc. Multicomponent vaccines
WO2000015238A1 (en) 1998-09-14 2000-03-23 Nabi COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
CA2365296A1 (en) * 1999-03-19 2000-09-28 Pierre Michel Desmons Vaccine
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
KR100922031B1 (ko) 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
ES2221651T3 (es) 2000-07-21 2005-01-01 Ortho-Mcneil Pharmaceutical, Inc. Compuestos carbamato para uso en la prevencion o tratamiento del dolor neuropatico y dolor asociado con la cefalea en racimos y migraña.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1412379B1 (en) 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
CA2469132A1 (en) 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
EP1481011A4 (en) 2002-03-05 2007-05-30 Inhibitex Inc MONOCLONAL AND POLYCLONAL ANTIBODIES THAT DETECT COAGULASENEGATIVE STAPHYLOKOCKE PROTEINS
JP2006506467A (ja) 2002-08-02 2006-02-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
JP2006510353A (ja) * 2002-10-03 2006-03-30 インターツェル・アクチェンゲゼルシャフト ハプトグロビン受容体リガンド結合と相互作用する分子の使用
AU2003295520B8 (en) 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
JP5102487B2 (ja) * 2003-03-07 2012-12-19 ワイス・ホールディングズ・コーポレイション 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体
JP4764820B2 (ja) * 2003-06-23 2011-09-07 バクスター・インターナショナル・インコーポレイテッド ワクチン用担体タンパク質
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US20070134263A1 (en) * 2004-02-18 2007-06-14 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
CA2566409C (en) 2004-05-11 2012-12-04 Liana Juliana Josephine Steeghs Neisseria meningitidis igtb lipo-oligo-saccharides as adjuvant
US20080085289A1 (en) * 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
KR20070085457A (ko) 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan

Also Published As

Publication number Publication date
NZ570805A (en) 2011-10-28
EA201101164A1 (ru) 2012-05-30
BRPI0710210A2 (pt) 2011-05-24
WO2007113222A3 (en) 2007-11-29
WO2007113222A2 (en) 2007-10-11
IL227934A (en) 2015-04-30
EP2476433A1 (en) 2012-07-18
EA200801839A1 (ru) 2009-08-28
JP2009531387A (ja) 2009-09-03
MX2008012405A (es) 2008-10-07
CR10348A (es) 2008-10-29
AU2007233705A1 (en) 2007-10-11
KR101541383B1 (ko) 2015-08-03
MX337528B (es) 2016-03-09
ZA200808246B (en) 2014-11-26
MA30343B1 (fr) 2009-04-01
EP1998802A2 (en) 2008-12-10
EA015833B1 (ru) 2011-12-30
KR20080111115A (ko) 2008-12-22
EA020459B1 (ru) 2014-11-28
AU2011201158A1 (en) 2011-04-07
EP2476434A1 (en) 2012-07-18
MY148405A (en) 2013-04-30
CN103169960A (zh) 2013-06-26
NO20083722L (no) 2008-12-19
US20100021503A1 (en) 2010-01-28
AU2011201158B2 (en) 2013-08-22
NZ595178A (en) 2013-03-28
IL193565A (en) 2013-10-31
CA2647441C (en) 2021-02-23
EP3141261A1 (en) 2017-03-15
CA2647441A1 (en) 2007-10-11
IL227934A0 (en) 2013-09-30
SG170090A1 (en) 2011-04-29
AU2007233705B2 (en) 2010-12-23
IL193565A0 (en) 2009-08-03
US20180104323A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
CR20150097A (es) Composición inmunogénica
BRPI0515316A (pt) compostos de imidazoquinolina
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
BRPI0911847B8 (pt) composições de pastilha de nicotina
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
CR9987A (es) Compuestos de lactama y métodos de uso de los mismos
MX2010001849A (es) Depsipeptidos ciclicos.
EP2537857A3 (en) Mutant forms of streptolysin O
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
ATE442153T1 (de) Zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
AR060182A1 (es) Polisacaridos capsulares tipo 5 y tipo 8 de cepas s. aureus de sobreproduccion
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
UA97359C2 (en) Immunogenic composition
WO2007117926A3 (en) Stable dental whitening compositions
GT200800252A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion
CR10382A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzazepinas, su preparacion, composiciones que las contienen y utilizacion
ECSP088897A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización
TW200806314A (en) Immunogenic composition
ATE504215T1 (de) Süssmittelzusammensetzungen
ECSP088650A (es) Compuestos de amido y su uso como productos farmaceuticos
BRPI0602661A (pt) composições em emulsão de silicone-em-água contendo retinóides
TW200637563A (en) Oral gel composition for releasing the pains caused by mucositis